Ignyta Company
%20.jpg)
Ignyta is a scientifically driven biotechnology company catalyzing personalized medicine in autoimmune diseases. Their goals are to revolutionize the quality of biomarkers and tests available to rheumatologists and patients to help them make better informed, more individualized treatment decisions; and to identify truly novel autoimmune disease targets for biopharmaceutical companies to enable the development of precise therapies for patients worldwide.
Investors
Connections from
Total Funding:
$375.5M
Acquisitions Number:
1
Headquarters:
San Diego, California, United States
Funding Status:
M&A
Employee Number:
101-250
Estimated Revenue:
Less than $1M
Last Funding Type:
Post-IPO Equity
Technology:
P4 Medicine
Investor Type:
For Profit
Investors Number:
5
Founded Date:
2011-01-01
Industry:
Biotechnology, Health Care, Health Diagnostics